U.S. FDA Approves Label Update for Sun Pharma’s Cosibelimab-ipdl in Advanced cSCC
The U.S. Food and Drug Administration (FDA) approved a label update for cosibelimab-ipdl (Unloxcyt, Sun Pharma) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced (la) CSCC who are not candidates for curative surgery or curative radiation.